SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 10.61 |
Enterprise Value ($M) | 32.46 |
Book Value ($M) | 15.58 |
Book Value / Share | 1.32 |
Price / Book | 0.68 |
NCAV ($M) | -6.24 |
NCAV / Share | -0.53 |
Price / NCAV | -1.70 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.76 |
Return on Assets (ROA) | -0.74 |
Return on Equity (ROE) | -7.71 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 1.36 |
Current Ratio | 1.84 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 36.64 |
Assets | 58.47 |
Liabilities | 42.88 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G | Uptown Capital, LLC | |||
13G/A | Iliad Research & Trading, L.P. | 9.13 | 102.12 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
53,198 | 313,928 | 16.95 | |
51,109 | 172,174 | 29.68 | |
54,758 | 210,549 | 26.01 | |
83,336 | 193,967 | 42.96 | |
(click for more detail) |
Similar Companies | |
---|---|
INTS – Intensity Therapeutics, Inc. | IRD – Opus Genetics, Inc. |
ITRM – Iterum Therapeutics plc | JSPR – Jasper Therapeutics, Inc. |
KALA – KALA BIO, Inc. |
Financial data and stock pages provided by
Fintel.io